Condition (MeSH)
Siderosis
ClinicalTrials.gov lists 4 trials for Siderosis or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
3 sections measured, none recorded · 1 not measured yet · 1 not computed
4 of the 4 trials are tagged with Siderosis itself; the rest are tagged with a narrower condition beneath it.
When did Siderosis trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 2 |
| 2020 | 1 |
| 2007 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 4 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Siderosis trials in? (1)
Shown in this order: phase order.
| Phase | Trials |
|---|---|
| Observational | 4 |
How many Siderosis trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 3 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Siderosis trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Pfizer | 1 |
Which publications cover Siderosis? (24)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies. | Neurology | 2024 | Yes |
| Infratentorial Superficial Siderosis and Spontaneous Intracranial Hypotension. | Annals of neurology | 2023 | Yes |
| Brain hemorrhage on 24h-CT and functional outcome in stroke patients with cerebral amyloid angiopathy features on pre-thrombolysis MRI treated with intravenous thrombolysis: A case series. | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association | 2023 | Yes |
| Cerebellar Superficial Siderosis in Cerebral Amyloid Angiopathy on 1.5T T2*-Weighted Imaging. | Cerebrovascular diseases (Basel, Switzerland) | 2023 | Yes |
| Vestibular Dysfunction in Patients With Superficial Siderosis of the Central Nervous System. | Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology | 2018 | Yes |
Showing 5 of 24 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Idiopathic pulmonary hemosiderosis | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
| Idiopathic pulmonary hemosiderosis | Point prevalence | Unknown | Europe | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.